Last updated: May 24, 2026
Dexilant (dexlansoprazole) is supplied in the US market primarily through a Takeda-led network for branded drug products, using contracted external manufacturing for bulk drug substance and finished dosage forms. The critical suppliers for procurement due diligence are (1) API and key intermediate manufacturers for dexlansoprazole, and (2) finished-dose contract manufacturers for Dexilant delayed-release capsules (dual delayed-release platform).
Because Dexilant supply arrangements and supplier-by-supplier listings vary by site, batch, and regulatory geography, the supplier set that matters for contracting and risk review is the set of current manufacturing sites listed on FDA approvals and commercial labeling, plus the API sources referenced in manufacturing-related regulatory filings (e.g., ANDAs/FDAs databases) and quality agreements.
What companies supply Dexilant (dexlansoprazole) capsules in the US?
Answer: Takeda owns the brand supply chain, while external contract manufacturers typically produce bulk and finished product. Supplier visibility is driven by FDA facility listings and labeling manufacturing sites.
Dexilant is a delayed-release capsule using a dual release dosing design. That product architecture increases the importance of: (a) layered tablet/pellet or layered granule manufacturing capability, (b) enteric coating and drug release profile validation, and (c) cGMP controls for dose uniformity across the two release phases.
What finished-dose manufacturing sites matter most for procurement?
For Dexilant purchasing and supplier risk review, the specific manufacturing facilities are the ones listed for:
- Finished dosage manufacturing (capsule fill/finish)
- Encapsulation and packaging
- Quality release testing, if performed on-site
- Potential secondary packaging locations used in US distribution
These are the sites that determine:
- Availability during peak demand
- Batch-level supply continuity
- Risk of shortages tied to facility downtime
- Lead times and change control impact on formulation performance
What API supply constraints affect dexlansoprazole?
Dexlansoprazole API suppliers must demonstrate:
- Robust synthesis control (key intermediates and impurity profiles)
- Consistent polymorph and solid-state behavior control
- Capability for enteric-coated compatibility and downstream stability
- Compliance with US cGMP expectations for drug substances used in NDA products
Because proton pump inhibitor (PPI) APIs are sensitive to impurity thresholds and stability, API supplier changes typically trigger extensive comparability packages and regulatory notification/approval paths.
Which API suppliers make dexlansoprazole drug substance?
Answer: API supply is typically sourced from qualified pharmaceutical API manufacturers outside Takeda, with the exact set tied to current commercial supply agreements and facility status.
In practical procurement terms, dexlansoprazole API sourcing is assessed via:
- The manufacturing sites named in drug substance regulatory documentation
- Confirmed supply chain qualification through quality agreements
- Batch release testing coverage and supply assurance terms
How do PPI API supplier choices change approval and change-control exposure?
For PPIs, changes in:
- API manufacturer
- key intermediate manufacturer
- synthesis route or control strategy
- impurity control strategy
can affect product stability and release acceptance. Those triggers can increase the chance of manufacturing delays, longer qualification cycles, or tighter specifications.
What contract manufacturers produce Dexilant (dexlansoprazole) capsules?
Answer: Dexilant finished-dose capsules are typically produced through contract manufacturing organizations (CMOs) operating under Takeda’s quality system and NDA-based change control.
Key CMO capability requirements for Dexilant include:
- Dual delayed-release manufacturing process control
- Enteric coating and layered release reproducibility
- Capsule filling with narrow acceptance ranges for dose uniformity
- Stability and dissolution alignment to NDA release specifications
- Packaging configuration that supports US market labeling requirements
What supplier risks create shortages or supply disruption for Dexilant?
Supply risk for Dexilant tends to concentrate around:
- Single-site dependency for a specific step (layering, coating, or encapsulation)
- Limits on capacity during surge demand
- Equipment downtime affecting coating/enteric processing lines
- Tight impurity specs in API that reduce the pool of qualified suppliers
- Regulatory change-control lead times when suppliers or sites change
What due diligence reduces execution risk with Dexilant suppliers?
Contracting teams typically validate:
- Regulatory status of facilities (inspection outcomes and compliance history)
- Documented master batch records and change control history
- On-time delivery metrics and batch failure rates
- Calibration and coating line validation status for layered release
- Comparator dissolution and stability data for any process or raw material changes
How does Dexilant’s dual delayed-release formulation affect supplier selection?
Dexilant is not a simple enteric-coated PPI tablet; it uses a dual delayed-release approach designed to spread drug release over time. This increases supplier selectivity.
Which manufacturing steps are bottlenecks?
The bottlenecks typically include:
- Formation of drug-containing layers/pellets/granules with controlled drug loading
- Enteric coating step with strict dissolution control
- Encapsulation and sealing
- Packaging to preserve product integrity
What CMO changeovers create the biggest delays?
Changeovers that most often delay supply are:
- Switching enteric coating supplier or polymer grade without equivalency
- Equipment line changes that alter coating thickness or curing conditions
- Changes in capsule fill method or mixing protocol affecting uniformity
What does the Orange Book list for Dexilant patents, and how does that relate to supplier sourcing?
Answer: Orange Book listings drive generic entry strategy, which changes commercial incentives for supplier expansion and alternative manufacturing capacity.
However, patent listings do not directly identify Dexilant capsule suppliers. Instead, they affect how potential entrants design manufacturing to minimize freedom-to-operate risks.
Do patent expirations or exclusivity changes influence supply agreements?
When exclusivity or key method-of-use and formulation patents near expiration, market participants increase:
- CMO capacity planning
- API supplier qualification for potential authorized generics
- internal redundancy for continuity planning
How do authorized generics or biosimilar pathways affect Dexilant supply?
Dexilant is an NDA small-molecule drug (not biologic), so the relevant competition pathway is generic ANDA, not a biosimilar.
What is the practical link between generic ANDAs and CMO/APIs?
ANDA filers typically qualify alternative CMOs and API sources to support:
- ANDA batch production
- validation at commercial scale
- bioequivalence and dissolution alignment with the reference listed drug
Competitive landscape: What generic or alternative PPIs compete with Dexilant and what that does to suppliers?
Dexilant competes in the PPI class with agents such as:
- esomeprazole (Nexium)
- omeprazole (Prilosec)
- lansoprazole (Prevacid)
- pantoprazole (Protonix)
- rabeprazole (Aciphex)
Supplier dynamics across PPIs can influence:
- shared API intermediate suppliers
- CMO capacity for enteric-coated delayed-release forms
- availability of enteric coating materials and encapsulation lines
If a CMO has multiple PPI programs, PPI-specific bottlenecks can cause substitution delays or production prioritization issues.
Key Takeaways
- Dexilant supply is Takeda-led but relies on external API and finished-dose manufacturing networks under NDA-based controls.
- Supplier selection for Dexilant must prioritize dual delayed-release manufacturing capability and robust enteric coating and dissolution control.
- Major procurement risk is capacity and change-control exposure, especially around API impurity specs and layered release manufacturing steps.
- Competitive pressure in the PPI class can reshape supplier availability, including shared CMO capacity and enteric coating supply chains.
FAQs
1) Are there multiple API sources for dexlansoprazole for Dexilant?
Commercial supply typically uses qualified backup sources over time, but the active set depends on current approvals, batch history, and quality agreements.
2) What manufacturing change is most likely to delay Dexilant supply?
Process or raw material changes that affect dual delayed-release dissolution behavior, particularly enteric coating process parameters or polymer grade, are high-friction.
3) Can a new CMO qualify Dexilant quickly?
Qualification is typically lengthy because dual delayed-release performance must be matched with cGMP comparability and stability data, and then integrated into Takeda’s regulatory change-control process.
4) Do Dexilant patents influence who can supply the product?
Patents affect generic/authorized competition incentives and may affect when suppliers are retooled for alternative production, but they do not directly list suppliers.
5) What supplier documentation should be required for dexlansoprazole API?
Batch release specifications tied to impurity profiles, stability protocol results, CoA/CoC history, and facility cGMP status through quality audits.
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. Drug Approval Reports and Labeling (access via Drugs@FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. Drugs@FDA: Dexilant (dexlansoprazole) product information and labeling. https://www.accessdata.fda.gov/scripts/cder/daf/
